Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
Parexel International-EPCU Baltimore, Baltimore, Maryland Moldova
ARENSIA Research Clinic, Chisinau Romania
Arensia Clinics S.R.L., Bucharest Spitalul Clinic Judetean De Urgenta Cluj, Cluj-Napoca United Kingdom
Parexel International Early Phase Clinical Unit, Harrow Simbec-Orion Clinical Pharmacology, Merthyr Tydfil